Shuffling for industrial innovation

OXFORD - Novo Nordisk A/S, one of the world's most established bioscience companies, is linking up with Maxygen Inc., one of the youngest companies, to develop the next generation of industrial enzymes and proteins. The companies have entered a licensing agreement and five-year R&D collaborative program

Read the full 460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE